Role of Salivary Bisphosphonates in Osteonecrosis of the Jaw in Myeloma Patients

唾液双磷酸盐在骨髓瘤患者下颌骨坏死中的作用

基本信息

  • 批准号:
    8053254
  • 负责人:
  • 金额:
    $ 15.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Osteonecrosis of the jaw (ONJ) is a recognized complication of bisphosphonate (BP) therapy that carries significant morbidity for multiple myeloma (MM) patients. Understanding the pathogenesis is crucial for early detection and therapy of ONJ. We hypothesize that ONJ pathogenesis has a soft tissue component contributing to bone necrosis. Once alveolar bone is exposed, an infectious biofilm will form, leading to further irritation of the tissues and subsequent stimulation of osteoclasts, with ensuing bone resorption and release of bone-bound BP into the oral cavity. In addition mucosal integrity is essential in protecting the underlying alveolar bone from exposure to oral pathogens and in providing blood supply to the cortical bone. Thus, sustaining a vicious cycle that will result in a non-healing mucosal lesion and bone necrosis, ONJ. We hypothesize that cytotoxic levels of free BP in the saliva initiate and/or impair soft tissue healing. This hypothesis is supported by our preliminary in vitro studies demonstrating that brief exposure to low levels of BP induced apoptosis and inhibited normal proliferation of gingival fibroblasts and oral epidermal mucosal cells. To test the hypothesis: aim 1 will focus on measurements of "free" BP in the saliva of MM patients with ONJ and a control cohort of MM patients without ONJ matched for the duration of BP exposure, age, MM treatment and MM status, a total of 60 patients. In aim 2 we will prospectively follow up 100 MM patients at the highest risk for developing ONJ, all selected based on the duration of BP exposure, age and MM status. Clinical, dental evaluations as well blood and salivary samples will be collected every 3 month for 18 month of follow up; additional samples will be collected at the time of any dental procedure and for those developing ONJ, expect 7-10 patients per year for this high risk group. Samples will be analyzed for those developing ONJ with regards to microbial species changes, BP levels and changes in inflammatory cytokines. These findings will establish the changes in BP pharmacokinetics after chronic use, the prospective study of microbial shifts and changes in cytokines and bone turnover markers will provide a predictive model for pathogenesis of ONJ that can be further developed prospectively for focused interventions and therapy of ONJ. PUBLIC HEALTH RELEVANCE: Survival of multiple myeloma patients has improved with the introduction of novel agents; there is need for research efforts to focus on better management of long-term therapy related side effects such as bisphosphonate-related osteonecrosis of the jaw. The proposed work will determine bisphosphonate pharmacokinetics and prospectively follow high-risk MM patients to identify changes in the oral bacterial species associated with osteonecrosis of the jaw. This will provide novel mechanisms to explain the delayed healing of the soft tissues in ONJ that could be further developed into focused therapeutic interventions.
描述(由申请方提供):颌骨骨坏死(ONJ)是双膦酸盐(BP)治疗的公认并发症,多发性骨髓瘤(MM)患者的发病率较高。了解ONJ的发病机制对于早期发现和治疗ONJ至关重要。我们假设ONJ的发病机制有一个软组织成分,有助于骨坏死。一旦牙槽骨暴露,将形成感染性生物膜,导致组织的进一步刺激和破骨细胞的后续刺激,随之而来的是骨吸收和骨结合BP释放到口腔中。此外,粘膜的完整性对于保护下面的牙槽骨免受口腔病原体的侵害以及为皮质骨提供血液供应是必不可少的。因此,维持一个恶性循环,将导致不愈合的粘膜病变和骨坏死,ONJ。我们假设唾液中游离BP的细胞毒性水平启动和/或损害软组织愈合。我们初步的体外研究表明,短暂暴露于低水平的BP诱导细胞凋亡,抑制牙龈成纤维细胞和口腔表皮粘膜细胞的正常增殖,这一假设是支持的。为了检验假设:目的1将集中于测量患有ONJ的MM患者和对照组的没有ONJ的MM患者的唾液中的“游离”BP,所述对照组在BP暴露持续时间、年龄、MM治疗和MM状态方面匹配,总共60名患者。在目标2中,我们将前瞻性随访100例发生ONJ风险最高的MM患者,所有患者均基于BP暴露持续时间、年龄和MM状态进行选择。在18个月随访期间,每3个月采集一次临床、牙科评价以及血液和唾液样本;在任何牙科手术时采集额外样本,对于发生ONJ的患者,预计该高风险组每年有7-10例患者。将分析发生ONJ患者的样本,包括微生物种类变化、BP水平和炎性细胞因子变化。这些发现将确立长期使用后BP药代动力学的变化,微生物变化以及细胞因子和骨转换标志物变化的前瞻性研究将为ONJ的发病机制提供预测模型,该模型可以进一步前瞻性地开发用于ONJ的集中干预和治疗。 公共卫生关系:随着新型药物的引入,多发性骨髓瘤患者的生存率有所改善;需要开展研究工作,重点关注更好地管理长期治疗相关的副作用,如双膦酸盐相关的颌骨骨坏死。拟议的工作将确定双膦酸盐的药代动力学和前瞻性地跟踪高危MM患者,以确定与颌骨骨坏死相关的口腔细菌种类的变化。这将提供新的机制来解释ONJ中软组织的延迟愈合,可以进一步发展为集中的治疗干预。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ashraf Z Badros其他文献

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
  • DOI:
    10.1186/2051-1426-1-s1-p30
  • 发表时间:
    2013-11-01
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Aaron P Rapoport;Edward A Stadtmauer;Dan T Vogl;Brendan Weiss;Gwendolyn K Binder-Scholl;Dominic P Smethurst;Jeffrey Finklestein;Irina Kulikovskaya;Minnal Gupta;Joanna E Brewer;Alan D Bennett;Andrew B Gerry;Nick J Pumphrey;Helen K Tayton-Martin;Lilliam Ribeiro;Ashraf Z Badros;Saul Yanovich;Gorgun Akpek;Naseem Kerr;Sunita Philip;Sandra Westphal;Levine L Bruce;Bent K Jakobsen;Carl H June;Michael Kalos
  • 通讯作者:
    Michael Kalos
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
多发性骨髓瘤相关肾功能损害的管理:国际骨髓瘤工作组的建议
  • DOI:
    10.1016/s1470-2045(23)00223-1
  • 发表时间:
    2023-07-01
  • 期刊:
  • 影响因子:
    35.900
  • 作者:
    Meletios A Dimopoulos;Giampaolo Merlini;Frank Bridoux;Nelson Leung;Joseph Mikhael;Simon J Harrison;Efstathios Kastritis;Laurent Garderet;Alessandro Gozzetti;Niels W C J van de Donk;Katja C Weisel;Ashraf Z Badros;Meral Beksac;Jens Hillengass;Mohamad Mohty;P Joy Ho;Ioannis Ntanasis-Stathopoulos;Maria-Victoria Mateos;Paul Richardson;Joan Blade;Evangelos Terpos
  • 通讯作者:
    Evangelos Terpos

Ashraf Z Badros的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ashraf Z Badros', 18)}}的其他基金

Role of Salivary Bisphosphonates in Osteonecrosis of the Jaw in Myeloma Patients
唾液双磷酸盐在骨髓瘤患者下颌骨坏死中的作用
  • 批准号:
    7787674
  • 财政年份:
    2010
  • 资助金额:
    $ 15.59万
  • 项目类别:
0514 GCC: A PHASE 1 STUDY OF SAHA IN COMBINATION WITH BORTEZOMIB IN RELAPSED
0514 GCC:SAHA 联合硼替佐米治疗复发的第一阶段研究
  • 批准号:
    7608162
  • 财政年份:
    2007
  • 资助金额:
    $ 15.59万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 15.59万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了